PEAK vs PHAT
PEAK (PEAK) versus Phathom Pharmaceuticals Inc (PHAT) — a side-by-side from cached financials, not a winner call.
PEAK (PEAK) common stock.
Phathom Pharmaceuticals Inc (PHAT) is a biotechnology company listed on US.
PEAK does not have a complete income-statement cache yet.
Latest reported PHAT revenue for 2024-12-31 was $55.3M. Net income was -$334.3M. Revenue was up 8001.5% from 2023-12-31 to 2024-12-31. PHAT currently screens at market cap $622.7M.
PHAT currently screens at market cap $622.7M.
Not investment advice. Open the PEAK and PHAT stock pages for the full models.
Not investment advice.